MACDALINE SCOTT: Open Payments
NPI 1750040184 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,998 in 125 payments from 12 companies in 2025. Trend: 2023 $1,276 · 2024 $1,528 · 2025 $2,998
Food & beverage: $2,887Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $466 |
| Teva Pharmaceuticals USA, Inc. | 17 | $465 |
| Janssen Pharmaceuticals, Inc | 13 | $452 |
| Otsuka America Pharmaceutical, Inc. | 15 | $309 |
| Vanda Pharmaceuticals Inc. | 12 | $295 |
| ABBVIE INC. | 17 | $278 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $203 |
| Lundbeck LLC | 8 | $201 |
| E.R. Squibb & Sons, L.L.C. | 6 | $144 |
| Neurocrine BioSciences, Inc. | 5 | $115 |
Products named: INVEGA SUSTENNA, REXULTI, FANAPT, VRAYLAR, ARISTADA, UZEDY, LYBALVI, CAPLYTA.
Industry payments across PA — which companies pay providers there.
